SIRT's acquisition price versus intrinsic value is really tough to comment upon, given that their value to GSK is primarily in their discovery prowess and that their lead candidate 'only' has Phase Ib results.
For acquisitions of late-stage candidates, that are more readily valued, I wonder if there have been any steals, possibly as a result of an inhospitable financing environment?
It should not happen because there will almost always be more than one BP interested, as we've agreed. But one never knows.
Market Data 
Markets 
AI
